Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc
AGNPF
Primary Symbol:
C.AGN
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 05, 2022 7:00am
New Press Release - Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that the United States Food and Drug...
read article.
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Dec 01, 2022 2:50pm
CEO Interview
The CEO of AGN.v AGNPF was recently featured on Market One to discuss their investigation into DMT as a treatment for strokes. Some highlights that stood out to me - Currently only around 15% of
...more
Q Precious & Battery Metals to Drill Initial 1000 metres at La Corne and McKenzie East Gold Projects, Quebec
posted Apr 18, 2024 9:00am by
Q Precious & Battery Metals Corp
-
|
The Company is planning for an initial 1,000 metres of diamond drilling scheduled for mid- June 2024, with VMS targets on the La Corne South project at proposed depths ranging from 50 to 300 metres below surface as modelled by the EM survey and noted in historic drilling. TMC Geophysique completed deep-penetrating Pulse-EM -Time Domain Electromagnetic (TDEM) surveying on the claims that targeted ...read more
(75)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Nov 30, 2022 5:07pm
DMT phase 1 study begins screening doseing to start in Dec
Algernon Pharmaceuticals Inc. (AGN.c AGNPF), has started screening subjects for its Phase 1 clinical study of IV DMT for the treatment of stroke. AGN should dose the first subject of the
...more
(268)
•••
stockpatrol
X
View Profile
View Bullboard History
Post by
stockpatrol
on Nov 29, 2022 5:29pm
AGN.c is currently two weeks into Phase 1 clinical trials fo
AGN.c is currently two weeks into Phase 1 clinical trials for DMT treatment of stroke. https://twitter.com/top_prospector/status/1597292188987453440 Phase 1's object is
...more
(40)
•••
StockDoctor101
X
View Profile
View Bullboard History
Post by
StockDoctor101
on Nov 28, 2022 12:54pm
Looking at AGN @ $2.47
I like the tight float of AGN. Seems to be holding around $2.5 but some promising results from their DMT trials could get it moving again. Phase II trials could also start as early as next year on
...more
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Nov 25, 2022 1:00pm
Article on AGN
Came across this article on the potential for DMT to become a breakthrough treatment for people who suffer a stroke. It also touches on AGN.c AGNPF and their phase-1 study they began earlier this
...more
(22)
•••
GoodLife60
X
View Profile
View Bullboard History
Post by
GoodLife60
on Nov 25, 2022 11:35am
Did I miss a news release?
Why is this dropping this time.
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Nov 24, 2022 1:46pm
Video with CEO
Found this video of the AGN.c AGNPF CEO featured on Market One discussing their investigation into DMT as a treatment for strokes. Some noteworthy things mentioned - Currently only around 15% of
...more
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Nov 23, 2022 3:03pm
AGN Begins Screening for Phase 1 Study
AGN.c AGNPF announced last week they began screening subjects for its Phase 1 clinical study of an intravenous formulation of AP-188 (DMT). The decision to investigate DMT and move it into human
...more
(268)
•••
stockpatrol
X
View Profile
View Bullboard History
Post by
stockpatrol
on Nov 22, 2022 5:49pm
Expecting AGN.c to reach phase 2 of DMT trials swiftly.
Expecting AGN.c to reach phase 2 of DMT trials swiftly. AGN.c has started screening subjects for its phase 1 clinical trials, since a few DMT trials at this stage have already
...more
(268)
•••
stockpatrol
X
View Profile
View Bullboard History
Post by
stockpatrol
on Nov 21, 2022 6:44pm
AGN.c starting to stabilize in the high $2 range.
AGN.c starting to stabilize in the high $2 range. https://twitter.com/StckMasterFlash/status/1592966259284799488 As we have seen in the past they're price can jump
...more
(268)
•••
stockpatrol
X
View Profile
View Bullboard History
Post by
stockpatrol
on Nov 18, 2022 6:25pm
AGN.c officially screening subjects for DMT Phase 1 clinical
AGN.c officially screening subjects for DMT Phase 1 clinical trials for treatment of stroke. https://twitter.com/StckMasterFlash/status/1592966259284799488 There will be a
...more
(83)
•••
biggonads
X
View Profile
View Bullboard History
Post by
biggonads
on Nov 17, 2022 2:54pm
AGN progress on DMT clinical stroke research program
Algernon Pharmaceuticals announces that they’ve initiated their DMT clinical stroke research program with their Phase 1 study in the Netherlands. The release today indicates the progress of this
...more
(53)
•••
waves1
X
View Profile
View Bullboard History
Post by
waves1
on Nov 16, 2022 2:25pm
AGN commences screening for DMT study subjects
AGN has commenced screening for the subjects in its Phase I DMT human stoke study! Conducted in the Netherlands, AGN expects to open enrolment shortly and dose the first subject of the study in
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 16, 2022 7:00am
New Press Release - Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study
VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has commenced screening subjects for...
read article.
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Positive PEA for Uranium-Vanadium Deposit After-tax NPV 8%: $227.7 million with IRR: 38.9%
Fokus Mining Welcomes Luc Gervais To Its Board Of Directors
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Q Precious & Battery Metals Contracts First Class Drilling for Quebec Projects
Why the Tonopah Gold Project is One to Watch
Targeting Nevada and Ontario for the Critical Minerals Supply Chain
Asset Sale Allows Biotech Company to Refocus on the High Value Dermatological Market